The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2019 | Ibrutinib in DLBCL: revelations from further analysis of PHOENIX
The Phase III PHOENIX trial (NCT01855750) enrolled non-germinal center B-cell-like DLBCL patients and treated them with ibrutinib in combination with R-CHOP; the results were dissapointing, but could there be more to this than meets the eye? Here, Wyndham Wilson, MD, PhD, Center for Cancer Research, National Cancer Institute, Bethesda, MD, discusses the analysis of the results according to age, which revealed a number of interesting facts. He also discusses the concordance between IHC and gene expression profiling for the subtyping of DLBCL. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
